To validate MDM2 as a potential therapeutic target for TP53 wild-type/PPM1D mutant cell lines, we combined data from Mutations, Copy Number Alterations (Cancer Cell Line Encyclopedia, Broad, 2019) and CRISPR screening data of 808 cancer cell lines (https://depmap.org/portal/; https://depmap.org/portal/; https://depmap.org/portal/) [23]. Here, TP53 is linked to cancer.